Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
08 Maio 2024 - 9:30AM
Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a
clinical-stage rare disease biopharmaceutical company developing
novel therapeutics for the treatment of pathologic mineralization
and intimal proliferation, today announced Doug Treco, Ph.D., CEO
and Chairman of Inozyme, will participate in a fireside chat at the
Bank of America Securities 2024 Health Care Conference on
Wednesday, May 15, 2024 from 6:40-7:10pm ET / 3:40-4:10pm PT.
A live webcast of the fireside chat can be
accessed from the Investor Relations section of Inozyme’s
website under events, where a replay of the event will also be
available for a limited time.
About Inozyme Pharma
Inozyme Pharma, Inc. is a clinical-stage rare
disease biopharmaceutical company developing novel therapeutics for
the treatment of diseases impacting the vasculature, soft tissue,
and skeleton. Inozyme is developing INZ-701, an enzyme replacement
therapy, to address pathologic mineralization and intimal
proliferation, which can drive morbidity and mortality in these
severe diseases. INZ-701 is currently in clinical development for
the treatment of ENPP1 Deficiency, ABCC6 Deficiency and
calciphylaxis.
For more information, please
visit https://www.inozyme.com/ or follow Inozyme
on LinkedIn, X, and Facebook.
Contacts
Investors:Inozyme PharmaStefan Riley, Senior Director of IR and
Corporate Communications(857) 330-8871stefan.riley@inozyme.com
Media: SmithSolve Matt Pera(973)
886-9150matt.pera@smithsolve.com
Inozyme Pharma (NASDAQ:INZY)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Inozyme Pharma (NASDAQ:INZY)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024